Another remarkable achievement has been accomplished by a lecturer from the FF UNAIR on the international stage. Dr. apt. Febri Annuryanti, S.Farm., M.Sc. successfully won the Best Poster Presenter award with Gold status at The 25th Asian Conference on Clinical Pharmacy (ACCP) 2026 held in Bangkok, Thailand.
The award was presented directly by the Board Members of ACCP on Friday, July 10, 2026 as a form of appreciation for the quality of research, scientific presentation, and Dr. Febri’s contribution to the development of pharmaceutical science at the international level.
At the conference, Dr. Febri presented her research titled “In-vitro Biocompatibility Studies of 3D-printed Triamcinolone Acetonide Implant for the Treatment of Posterior Ocular Diseases.” This research examined the biocompatibility of Triamcinolone Acetonide implants based on 3D printing technology as one of the therapeutic innovations for treating diseases in the posterior segment of the eye. This innovation is expected to support the development of more effective and safe drug delivery systems oriented toward improving healthcare service quality.
This success serves as evidence that FF UNAIR lecturers are capable of producing quality research that is recognized by the international scientific community. This award simultaneously strengthens the position of FF UNAIR as an institution that actively contributes to the development of knowledge, particularly in the field of clinical pharmacy and drug delivery technology.
The active participation of FF UNAIR lecturers in international scientific forums such as ACCP 2026 also represents the faculty’s commitment to promoting research culture, global collaboration, and dissemination of research findings to the world scientific community. Through this achievement, it is hoped that more innovations from the FF UNAIR academic community will be able to provide solutions to various healthcare challenges while enhancing the reputation of UNAIR at the international level.
The achievement attained by Dr. Febri Annuryanti aligns with FF UNAIR’s commitment to supporting the achievement of SDGs, particularly SDG 3 (Good Health and Well-being) through the development of therapeutic health innovations, and SG 9 (Industry, Innovation and Infrastructure) through strengthening research and innovation in pharmaceutical technology.
